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PODIUM SESSION II: MIXED TREATMENT COMPARISON 
METHODOLOGY AND APPLICATIONS
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THE OUTCOME FOR DECISION-MAKERS?
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Ireland; 3St. Vincents University Hospital, Dublin Academic Healthcare, Dublin, Ireland
BACKGROUND: An incremental cost-effectiveness ratio is calculated by dividing the 
difference in cost of an intervention by the difference in effect. In the absence of head 
to head trials, it is often necessary to combine evidence from placebo-controlled trials 
of different treatments and thereby derive an estimate of effect of one treatment against 
another. There are formal methods to do this and various models can be used. We 
present four different models and examine whether using different models can change 
the conclusion of the economic evaluation in rheumatoid arthritis (RA). METHODS: 
A literature review was carried out and the relevant data were extracted according to 
deﬁ ned inclusion criteria. The outcome measures chosen were American College of 
rheumatology (ACR) 20 and 50 at 6 months. The MTC was carried out in WinBUGS 
and the method used was that by Nixon et al.[1]. This model allows inclusion of 
methotrexate as a parameter. We then used the four different estimates from each of 
the models in an RA model. RESULTS: The four different models differed in whether 
random or ﬁ xed effect was applied to the treatment or to methotrexate. Pairwise risk 
ratios (RR) are presented. The RR differ slightly for the same drug using the different 
models. Both the positioning of the ICERs on the CE plane and the probability of 
cost-effectiveness change from model to model. CONCLUSIONS: We see a difference 
in the results of using different models for MTC. However, the relative positioning of 
the estimates remains the same. Therefore, in deciding which method to choose in the 
case of biological agents, it is unlikely that the choice of model will impact greatly on 
the overall decision.
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CONDUCTING A MIXED TREATMENT COMPARISON (MTC) IN A 
SPECIFIC POPULATION: POSTMENOPAUSAL WOMEN WITH 
METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER 
WHICH OVEREXPRESSES HER2
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OBJECTIVES: To estimate the relative treatment effects on progression free survival 
(PFS) and overall survival (OS) of trastuzumab plus an aromatase inhibitor (AI), lapa-
tinib plus an AI, and AI monotherapy (anastrozole, letrozole, or exemestane) in 
postmenopausal women with untreated metastatic hormone receptor positive breast 
cancer which overexpresses HER2. METHODS: A systematic literature review was 
conducted in MEDLINE, MEDLINE-IN-PROCESS, EMBASE, Cochrane CENTRAL, 
Web of Science Proceedings, and BIOSIS to retrieve relevant randomized clinical trials. 
Heterogeneity and inconsistency were discussed with clinical experts and assessed 
statistically. An MTC was developed within the Bayesian framework using noninfor-
mative priors. It was decided a priori to investigate whether AIs could be considered 
as a class, through the evaluation of hazard ratios between single agents. As few trials 
focused on the exact target population, extensive sensitivity analyses were planned. 
RESULTS: The base-case analysis indicated no signiﬁ cant difference between AIs on 
PFS. Combined therapies were signiﬁ cantly more effective than AIs: the hazard ratios 
were estimated at 0.55 (95% CrI: [0.41; 0.74]) for trastuzumab + AI and 0.71 (95% 
CrI: [0.53; 0.96]) for lapatinib + AI. Although the probability of being best varied in 
the sensitivity analyses, trastuzumab + AI was always associated with the highest 
probability of best efﬁ cacy. The effect on OS was similar across AIs. No signiﬁ cant 
difference was found between the two combination therapies, which were associated 
with high probabilities of best efﬁ cacy (48% for trastuzumab + AI and 50% for lapa-
tinib + AI). The sensitivity analyses indicated that adjustment for cross-over had an 
important impact on the OS results. CONCLUSIONS: Our study conﬁ rmed that 
anastrozole, letrozole, and exemestane had similar efﬁ cacy with respect to PFS and 
OS and that combined therapies were associated with signiﬁ cantly improved PFS 
compared to AIs. Conducting an MTC in this speciﬁ c population was addressed 
through clinical and statistical assessments of heterogeneity and inconsistency, and 
extensive sensitivity analyses.
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COMPARATIVE EFFECTIVENESS OF ANTIDEPRESSANTS (AD) IN THE 
TREATMENT OF THE ELDERLY WITH MAJOR DEPRESSIVE DISORDER 
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ANALYSIS
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OBJECTIVES: To estimate the probability of clinical response, remission, and treat-
ment withdrawal of antidepressants including TCAs, SSRIs, mirtazapine, buproprion, 
and SNRIs in elderly patients with MDD using indirect comparison (MTC) and meta-
regression (MR) methods. METHODS: Published systematic reviews of AD in elderly 
patients with MDD were used to extract data from RCTs of comparator treatments 
reporting response or remission or treatment withdrawal. Studies with less than 6 
weeks duration, open label extension studies, and studies in patients with signiﬁ cant 
dementia were excluded. Bayesian MTC and MR analyses, enabling indirect compari-
sons of interventions while respecting randomization, were performed using OpenBugs 
3.0.2, adjusting for placebo control, baseline disease severity, treatment duration, age, 
patients with late onset depression as study, or arm level covariates as appropriate. 
Assuming similar class efﬁ cacy TCAs and SSRIs were grouped. RESULTS: The ﬁ nal 
data set included 40 studies, with 87 comparator arms. Placebo control was associated 
with a reduction in the log odds ratio (LOR) of response versus placebo for all treat-
ments. Severity and publication year was marginally correlated with response. Poste-
rior median predicted response and remission rates in non-placebo-controlled studies 
ranged between 71.9% (buproprione) and 77.1% (duloxetine), and remission between 
29.4% (SSRIs), 42.7% (duloxetine), and 58.1% (TCAs). Predicted withdrawal rates 
for non-placebo-controlled studies vary between 25.7% (duloxetine) and 40% (ven-
lafaxine). Remission results were sensitive to how the mean placebo incidence across 
studies was modeled. CONCLUSIONS: In the absence of head-to-head clinical trials, 
this analysis provides comparative estimates of relative treatment effect of AD among 
elderly with MDD while statistically taking into account heterogeneity. Although 
statistically not different, results suggest that among the elderly, duloxetine and TCAs 
produce the largest clinical response and remission rates, with relatively favorable 
withdrawal rates for duloxetine.
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MIXED TREATMENT COMPARISON (MTC) OF ANTIFUNGAL DRUGS 
FOR PROPHYLAXIS TREATMENT AGAINST INVASIVE FUNGAL 
INFECTIONS (IFIS) IN PATIENTS RECEIVING CHEMOTHERAPY FOR 
HEMATOLOGICAL MALIGNANCIES OR ALLOGENEIC HEMATOPOIETIC 
STEM CELLS TRANSPLANTATION
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OBJECTIVES: Neutropenic patients treated with chemotherapy for hematological 
malignancies and recipients of allogeneic hematopoietic stem cells transplantation 
(HSCT) are at high risk of acquiring invasive fungal infections (IFIs). Prognoses for 
IFIs are poor in terms of mortality and morbidity. An important factor in improving 
outcome is early treatment with antifungal agents. Early treatment, however, is com-
plicated by a number of factors, including poor diagnostic measures. As a conse-
quence, antifungal prophylaxis may be an effective strategy. Use of antifungal 
prophylaxis remains a matter of controversy, without a clear consensus on the choice 
of drug treatment. In this study, we used mixed treatment comparison (MTC) meth-
odologies to compare the effectiveness of different antifungal drugs used in prophy-
laxis treatments against IFIs in high-risk patients. METHODS: Through systematic 
and transparent methodologies, MTC techniques allow for the combination of evi-
dences from different sources and as a result may provide information where none 
exists or where direct comparisons are incomplete. For the estimation of effectiveness, 
we collected evidence on proven or probable IFIs from 13 different randomized clinical 
trials (RCTs). Comparisons of interest included placebo, ﬂ uconazole, itraconazole, 
voriconazole, and micafungin. The MTC analyses were carried out through the appli-
cation of Bayesian hierarchical models. RESULTS: Signiﬁ cant evidence was found on 
the superiority of all study drugs versus placebo for preventing IFIs. Furthermore, 
MTC analyses indicated that the probability of acquiring an IFI after voriconzole 
prophylaxis is signiﬁ cantly lower than after ﬂ uconazole prophylaxis (dOR = 0,17 95% 
CI = [0.03, 0.94]). Comparisons between all other antifungals yielded no signiﬁ cant 
differences in incidence of IFIs. CONCLUSIONS: After the application of MTC 
methodologies on RCT evidence, the authors found evidence suggesting that prophy-
laxis with antifungals is superior to placebo and prophylaxis with voriconazole is 
superior to ﬂ uconazole regarding reduction in incidence of IFIs. 
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RETROSPECTIVE ANALYSIS OF TECHNOLOGY APPRAISALS 
CONDUCTED BY UK’S NATIONAL INSTITUTE FOR HEALTH AND 
CLINICAL EXCELLENCE (NICE) IN SEVERAL CANCER INDICATIONS: 
HIGHER EVIDENCE BARRIERS FOR TARGETED THERAPIES?
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OBJECTIVES: We undertook a retrospective analysis of NICE technology appraisals 
in NSCLC, hematological malignancies, gastric and breast cancer, and compared 
submission evidence with ﬁ nal NICE recommendation. METHODS: The analysis was 
based on a review of published appraisals on the NICE website from 2007 to 2010. 
RESULTS: Over the past 3 years, NICE completed 15 appraisals in the indications of 
NSCLC, hematological malignancies, and gastric and breast cancer. Ten of these 
appraisals were of targeted therapies. A total of ﬁ ve out of 15 appraisals were not 
recommended mainly because of weak clinical evidence surrounding efﬁ cacy. One of 
these technologies, Lapatinib, was not recommended for breast cancer despite the 
manufacturer offering a patient-access scheme. Focusing on the 10 appraisals that 
received positive recommendation, four appraisals received unconditional reimburse-
ment. Rituximab is the only targeted therapy to receive unconditional reimbursement 
because it was cost-effective (<£30, 000 per QALY) due to the strong clinical evidence 
that demonstrated PFS >10 months compared to chemotherapy in CLL. The remaining 
